Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects.
about
Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performanceCentral effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography.Clinical utility and patient adherence with ebastine for allergic rhinitis.Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers.Review of fexofenadine in the treatment of chronic idiopathic urticaria.Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios.Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial.Transporter-mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target.Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteersAntihistamines in dermatology.Pediatric allergic rhinitis: antihistamine selection.Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines.Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis.Prevalence of alcohol and drug use in injured British Columbia drivers.Impaired cognition and attention in adults: pharmacological management strategies.Effects of L-histidine depletion and L-tyrosine/L-phenylalanine depletion on sensory and motor processes in healthy volunteers.Histamine H1 receptor blockade predominantly impairs sensory processes in human sensorimotor performance.Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.Xanthii Fructus inhibits allergic response in the ovalbumin-sensitized mouse allergic rhinitis model.Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig.The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers.Effects of second-generation histamine H1 receptor antagonists on the active avoidance response in rats.Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance.A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance.Histamine H1-receptor blockade in humans affects psychomotor performance but not memory.Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.Levocetirizine and rupatadine in chronic idiopathic urticaria.The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.Verbal memory performance during subchronic challenge with a selective serotonergic and a mixed action antidepressant.
P2860
Q28289605-207A1BA2-1113-460C-BD1F-DF4F25A14C7CQ34337549-14256ECC-FEFF-44EB-A079-040C5F467F00Q34413618-79D27AC1-964B-453A-912E-FA6D9E8ABF90Q34521823-E374E42A-F344-448E-94BC-BA6B5377B552Q34975901-4CBFB3E8-7A73-4F06-9206-806B2A339BE4Q34982550-26C6DEB2-5BEA-400F-BC79-CE8C2177B7CDQ35050198-ED329E4C-EF87-476F-AE21-7E2FAF33A40CQ35761679-C650B6BE-60E9-4D98-A567-32B558301A43Q35904482-08E99FFF-5FAE-41A3-ACDB-169EA4004062Q36193211-7B29F6DD-6917-4EFF-AD49-F89B547F0513Q36279844-F6BC4409-F7B0-4CE1-9079-0A8B3B7C6261Q36309636-90037E88-C5E3-45AE-B497-0229F0DDCEFEQ36458473-5ADB93C4-7DF0-44FC-81D2-6598323E34E6Q36707458-874B3F69-EFD2-4A58-A376-C966D9659286Q37125488-EE414C10-4CE1-40AD-BE7A-C7E4049E16E2Q37230871-59909505-A26D-416B-BDC7-BA50C4567933Q37230876-DA3B0FC0-AEA5-4568-8EDD-B6B0182E043DQ37410744-4D0CD8B6-C379-42C5-B3E0-EABED909A57BQ41778930-EC202DA6-9E09-4D7C-AE78-DCD99F7E4701Q42015392-92A11363-F3ED-4304-AE9E-79354BFFD3C7Q42626124-74FF6F0D-A1E7-4936-95CC-51C7BAA6C8EAQ43743717-DCE658AD-CF31-40BC-9119-58AA6EB768A6Q43987756-CAF4972A-C91B-40D0-965C-199567D45821Q44287626-1135841F-873C-4119-8334-6FCFAB1B1275Q45043892-4B37A916-F737-48EA-B037-1FA1F55FC305Q46713303-EF060509-3F0C-4809-A909-EBF944E7C73DQ46798714-69B0A499-DCCE-44E5-B7D3-6D47F78D6074Q47933632-DEFC801A-906D-4577-8DFE-4DF7A0D3490EQ48055791-300D66EC-A876-4072-9AA6-B3772B453572Q50919551-11FB380A-FDE0-4C28-B86E-08B4C83E2E23Q51978697-B60CF346-0245-444A-9EF3-D0697441986B
P2860
Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Antihistamines: models to asse ...... safety and other side-effects.
@ast
Antihistamines: models to asse ...... safety and other side-effects.
@en
type
label
Antihistamines: models to asse ...... safety and other side-effects.
@ast
Antihistamines: models to asse ...... safety and other side-effects.
@en
prefLabel
Antihistamines: models to asse ...... safety and other side-effects.
@ast
Antihistamines: models to asse ...... safety and other side-effects.
@en
P2860
P1476
Antihistamines: models to asse ...... safety and other side-effects.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2222.1999.0290S3133.X
P478
29 Suppl 3
P577
1999-07-01T00:00:00Z